Because of study heterogeneity, no meta-analyses were performed. No RCTs reported any statistically significant improvements in overall or progression-free survival or reduced toxicity with ascorbate relative to control arm. Evidence for ascorbateâ€™s antitumor effects was limited to case reports and observational and uncontrolled studies. 